Sanofi (SNY) Receivables Refunds (2016 - 2025)
Sanofi (SNY) has disclosed Receivables Refunds for 11 consecutive years, with $462.1 million as the latest value for Q4 2025.
- Quarterly Receivables Refunds fell 40.27% to $462.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $462.1 million through Dec 2025, down 40.27% year-over-year, with the annual reading at $448.5 million for FY2025, 42.76% down from the prior year.
- Receivables Refunds hit $462.1 million in Q4 2025 for Sanofi, down from $773.7 million in the prior quarter.
- In the past five years, Receivables Refunds ranged from a high of $773.7 million in Q4 2024 to a low of $381.6 million in Q4 2022.
- Historically, Receivables Refunds has averaged $547.6 million across 5 years, with a median of $462.1 million in 2025.
- Biggest five-year swings in Receivables Refunds: plummeted 51.39% in 2021 and later surged 83.9% in 2024.
- Year by year, Receivables Refunds stood at $700.1 million in 2021, then plummeted by 45.5% to $381.6 million in 2022, then rose by 10.25% to $420.7 million in 2023, then soared by 83.9% to $773.7 million in 2024, then crashed by 40.27% to $462.1 million in 2025.
- Business Quant data shows Receivables Refunds for SNY at $462.1 million in Q4 2025, $773.7 million in Q4 2024, and $420.7 million in Q4 2023.